Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,416.18 -8.67 -0.05%
S&P 500 1,863.64 1.33 0.07%
NASDAQ 4,095.10 8.88 0.22%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

AstraZeneca Applauds the Release of New U.S. Guideline for Management of Blood Cholesterol

  AstraZeneca Applauds the Release of New U.S. Guideline for Management of
  Blood Cholesterol

     Guideline supports use of CRESTOR^® (rosuvastatin calcium) to lower
                  cholesterol in patients at increased risk

Business Wire

WILMINGTON, Del. -- November 12, 2013

AstraZeneca (NYSE:AZN) today announced their support of the release of the
“2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce
Atherosclerotic Cardiovascular Risk in Adults,”  which recommends use of
statin therapy for patients across four major groups at risk for a heart
attack, stroke or major cardiovascular event. This guideline was issued
jointly by the American College of Cardiology (ACC) and American Heart
Association (AHA).

The guideline recommends moderate- or high-intensity statin therapy for:

  * Patients who have cardiovascular disease (CVD);
  * Patients with an LDL-C, or “bad” cholesterol level of 190 mg/dL or higher;
  * Patients with Type 2 diabetes who are between 40 and 75 years of age;
  * Patients without CVD or diabetes who are between 40 and 75 years of age
    with an LDL-C of 70-189 mg/dL and an estimated 10-year risk of
    cardiovascular disease of 7.5 percent or higher

“AstraZeneca has long advocated for and educated about the importance of
cardiovascular risk assessment, lifestyle change, and aggressive cholesterol
lowering in patients at increased risk, and we are pleased that the new
guideline provides physicians with clear definitions of these statin-eligible
patients,” said Dr. Philip de Vane, Executive Director, U.S. Medical Affairs,
AstraZeneca. “This reinforces the importance of CRESTOR as an appropriate
treatment option in increased-risk patients.”

In a 6-week multicenter, double-blind, placebo-controlled, dose-ranging study
in patients with hyperlipidemia, CRESTOR 5-40 mg has been shown to provide a
45%-63% reduction in LDL-C versus 7% with placebo. Furthermore, in high-risk
patients in the ECLIPSE trial, CRESTOR reduced LDL-C significantly more than
atorvastatin at each compared dose at each time point.

This guideline identifies patients most likely to benefit from statin therapy
and for the first time distinguishes recommended intensity of statin therapy
for specified patient groups.

“This new guideline is based on a review of multiple statin studies, including
studies from the CRESTOR clinical trial program,” added Dr. de Vane. “As
leaders in the field of cardiovascular disease, we are pleased that our
research helped to inform the development of this important guideline.”

For a copy of the “2013 ACC/AHA Guideline on the Treatment of Blood
Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults,” please

Approved Uses for CRESTOR^® (rosuvastatin calcium) Tablets

When diet and exercise alone aren't enough, adding CRESTOR can help. In
adults, CRESTOR is prescribed along with diet to lower high cholesterol and to
slow the buildup of plaque in arteries as part of a treatment plan to lower
cholesterol to goal.

CRESTOR is also prescribed to reduce the risk of heart attack and stroke in
people without known heart disease but at increased risk based on age (men 50
years and older, women 60 years and older), elevated blood levels of hsCRP (a
sign of inflammation that can be associated with increased risk of
cardiovascular events), plus at least one additional risk factor (such as high
blood pressure, low HDL "good" cholesterol, smoking, or family history of
early heart disease).

Important Safety Information about CRESTOR

CRESTOR is not right for everyone. Do not take CRESTOR if you are nursing,
pregnant or may become pregnant; have liver problems; or have had an allergic
reaction to CRESTOR. Your doctor should do blood tests to check your liver
before starting treatment and if you have symptoms of liver problems while
taking CRESTOR. Call your doctor right away if you have unexplained muscle
pain or weakness, especially with fever; have muscle problems that do not go
away even after your doctor told you to stop taking CRESTOR; feel unusually
tired; or have loss of appetite, upper belly pain, dark urine, or yellowing of
skin or eyes. These could be signs of rare but serious side effects. Elevated
blood sugar levels have been reported with statins, including CRESTOR. The
most common side effects may include headache, muscle aches, abdominal pain,
weakness, and nausea. Memory loss and confusion have also been reported with
statins, including CRESTOR. Tell your doctor and pharmacist about other
medicines you are taking.

Talk to your doctor about prescription CRESTOR.

Please read the full Prescribing Information.

If you have any questions concerning prescription-only CRESTOR, please visit or contact AstraZeneca at 1-800-CRESTOR.



CRESTOR has received regulatory approval in more than 100 countries worldwide.
CRESTOR is backed by clinical research that spans 13 years, including over 120
ongoing or completed clinical trials and includes more than 67,000 patients

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a
primary focus on the discovery, development and commercialization of
prescription medicines for gastrointestinal, cardiovascular, neuroscience,
respiratory and inflammation, oncology and infectious disease. AstraZeneca
operates in over 100 countries and its innovative medicines are used by
millions of patients worldwide.

For more information about AstraZeneca in the U.S. or our AZ&Me™ Prescription
Savings programs, please visit: or call 1-800-AZandMe

CRESTOR is a registered trademark, and AZ&Me is a trademark of the AstraZeneca
group of companies.

©2013 AstraZeneca. All rights reserved.

2927900 11/13


Media Inquiries:
Elizabeth Renz, 302-885-1936
Michele Meixell, 302-885-6351
Sponsored Links
Sponsored Links